COVID-19 Update: Our team is ready to serve you. Get Your Free Mesothelioma Guide

Mesothelioma Stage 1

Stage 1 is the earliest point in mesothelioma’s development. During this stage, the cancer has not spread beyond the lining of the lungs or abdomen. Stage 1 mesothelioma patients have the best prognosis and are usually good candidates for life-extending surgeries and other treatments. Unfortunately, because symptoms can be vague and gradual in onset, it is very rare to receive a stage 1 diagnosis.

Get a Free Mesothelioma Guide

What Is Stage 1 Mesothelioma?

Stage 1 mesothelioma is the earliest of mesothelioma’s four stages. These stages come from the tumor-node-metastasis (TNM) staging system — a globally recognized method for determining how far a patient’s cancer has spread.

Stage 1 mesothelioma may refer to two types of mesothelioma:

  1. Pleural mesothelioma: Pleural mesothelioma is the only officially-staged type, using the TNM cancer staging system. At this stage, the cancer is only on one side of the chest and remains in the lining of the lungs. It has not yet spread to nearby lymph nodes or to distant parts of the body.
  2. Peritoneal mesothelioma: Peritoneal mesothelioma may also be categorized as stage 1 using a modified TNM staging system proposed by medical professor Tristan D. Yan and his associates. Stage 1 peritoneal mesothelioma has not spread past the lining of the abdomen.

Doctors know too little about pericardial mesothelioma to properly stage it. The disease may, instead, be described as localized, regional, or distant using the older LRD staging system or simply, early or advanced.

Quick Facts About Stage 1 Mesothelioma

  • It is rare for mesothelioma patients to be diagnosed during stage 1 because symptoms may not even be present.
  • A 2017 study published in Lung Cancer International found that only 16% of pleural mesothelioma and 5% of peritoneal mesothelioma patients were diagnosed during stage 1.
  • The American Cancer Society found that 20% of patients diagnosed with localized (early-stage) pleural mesothelioma survived at least 5 years after diagnosis.

How Stage 1 Mesothelioma Develops

Mesothelioma is notorious for its long latency period — the time that passes between being exposed to a cancer-causing substance and when symptoms first appear. After a patient is exposed to asbestos, the main cause of pleural mesothelioma, this latency period lasts about 20-50 years.

Stage 1 mesothelioma develops after asbestos fibers get stuck in the lining of the lungs (pleura) or abdomen (peritoneum). These fibers irritate nearby cells, eventually damaging DNA and triggering out-of-control cell growth. This unchecked growth forms tumors on the lining of the organs.

The TNM staging system describes stage 1 pleural mesothelioma’s development using sub-stages.

Stage 1 pleural mesothelioma has two sub-stages of development:

  1. Stage 1A Mesothelioma: Stage 1A of the TNM staging system describes a pleural mesothelioma diagnosis in which cancer is only on one side of the chest, remaining only in the thin membrane covering the chest cavity. It has not yet reached the lining of the lungs (the pleura).
  2. Stage 1B: Stage 1B is slightly more advanced, describing pleural mesothelioma that remains localized to one side of the chest, but which has spread to the pleura as well as the chest wall lining.

As stage 1 mesothelioma develops, it may begin to cause mild symptoms that are still difficult to identify as signs of mesothelioma.

Stage 1 Mesothelioma Symptoms

Many patients do not experience any mesothelioma symptoms during the earliest stage of the disease.

However, some patients may experience the following stage 1 mesothelioma symptoms:

  • Dry, persistent cough
  • Chest pain
  • Shortness of breath
  • Slight difficulty breathing

Fluid buildup in the chest (pleural effusions) may begin during stage 1, causing the above symptoms. However, these vague, mild symptoms are often mistaken for less serious illnesses such as a cold, flu, pneumonia, or bronchitis.

How to Identify Stage 1 Mesothelioma

Most mesothelioma patients have no symptoms very early into the disease’s progression, making it extremely difficult to identify stage 1 mesothelioma without medical equipment.

Stage 1 mesothelioma is usually discovered by accident in the course of doing tests for another medical issue or as part of regular cancer screening for a high-risk patient.

Patients may greatly increase their chances of catching mesothelioma early by telling their doctor about any asbestos exposure history they may have.

Stage 1 Mesothelioma Diagnosis

Doctors rarely make a mesothelioma diagnosis at stage 1 because patients either experience no symptoms or vague symptoms.

Even when someone with mesothelioma happens to get an imaging test done, the small stage 1 mesothelioma tumor may be hard to see.

However, two image scan features may alert doctors to stage 1 mesothelioma:

  • Abnormal tissue masses in the chest area
  • Pleural effusions

Seeing either of these in a chest X-ray may prompt a doctor to investigate further and perform a biopsy, hopefully leading to an early diagnosis.

Stage 1 Diagnosis and Staging Systems

When doctors are able to confirm that a patient has mesothelioma, they use a staging system to determine how far the disease has progressed.

Today, the most widely accepted system for pleural mesothelioma diagnosis is the TNM system.

However, other systems exist, each with their own way of describing stage 1 or early-stage pleural mesothelioma.

Stage 1 Pleural Mesothelioma Diagnosis by Staging System

Butchart System

The disease remains contained in the pleura.

Brigham System

The disease can be surgically removed and has not yet spread to the lymph nodes.

TNM System

The disease remains on one side of the chest in the lining of the chest wall. The pleura may be cancer-free (1A) or cancer may have spread to the pleura (1B).

While the Brigham system is not often used anymore, the Butchart system remains popular in some parts of the world.

Stage 1 Mesothelioma Prognosis

A mesothelioma prognosis describes the likely course the disease will take. As the earliest stage, stage 1 mesothelioma has the best prognosis and the most treatment options.

Stage 1 Mesothelioma Life Expectancy

Life expectancy describes the average amount of time a patient can expect to live after being diagnosed. Naturally, patients diagnosed during stage 1 have the longest life expectancy by stage.

A 2019 study of 888 pleural and peritoneal mesothelioma patients found the median life expectancy of stage 1 patients was 20 months compared to 15 months for all 888 patients.

Stage 1 Mesothelioma Survival Rate

A mesothelioma survival rate measures the percentage of people with the disease who survive for a certain amount of years after diagnosis.

As with life expectancy, patients diagnosed with stage 1 mesothelioma can expect comparatively high survival rates.

The tables below reflect mesothelioma life expectancy data from a 2017 study published in Lung Cancer International. Taken from over 11,000 patients from 1973–2011, it shows how the stage at diagnosis affects survival rates.

The study translated the TNM staging system into the LRD system in the following way:

  • Localized: Stage 1 mesothelioma
  • Regional: Stage 2, 3, and 4 mesothelioma that has not spread to distant body parts
  • Distant: Stage 4 mesothelioma that has spread to other parts of the body

This translation was applied to both pleural and peritoneal mesothelioma.

Survival Rates for Pleural Mesothelioma by Stage

Mesothelioma Stage 1-Year Survival Rate

5-Year Survival Rate

Localized

41%

6%

Regional

40% 4%
Distant 32%

3%

Survival Rates for Peritoneal Mesothelioma by Stage

Mesothelioma Stage 1-Year Survival Rate 5-Year Survival Rate

Localized

74% 26%
Regional 55%

19%

Distant 40%

11%

Stage 1 mesothelioma patients live longer, in part, because their early diagnosis allows them to seek critical life-extending treatment that may be unavailable to later-stage patients.

Stage 1 Mesothelioma Treatment

Stage 1 mesothelioma patients are usually good candidates for curative mesothelioma treatments — medical procedures performed to extend a patient’s life.

Surgery

In general, stage 1 patients are good candidates for mesothelioma surgery. At this stage, surgeons are usually able to completely remove all visible parts of a tumor.

However, many factors may influence whether a patient is a candidate for surgery:

  • Stage: Tumors that are relatively small and contained in one area (localized) are more likely able to be surgically removed.
  • Cell type: Many doctors believe only epithelioid and mixed/biphasic cell types may be resectable.
  • Location: Tumors that form close to vital organs may be too risky to remove through surgery.
  • Patient health: Surgery for mesothelioma can be dangerous and incredibly taxing on the body. Even if a patient is diagnosed early, if they are in poor health, surgery may not be offered as it would be unsafe.

Common stage 1 mesothelioma surgery options include:

  • Extrapleural pneumonectomy (EPP)
  • Pleurectomy with decortication (P/D)
  • Cytoreduction with hyperthermic intraperitoneal chemotherapy (HIPEC)

Although surgery is often effective for stage 1 patients, it may leave behind cancer cells that are not visible to surgeons. These cells quickly re-form tumors. As such, most doctors will also recommend chemotherapy or radiation to destroy the remaining cancer.

Chemotherapy

Chemotherapy, a type of cancer treatment that uses special drugs to kill cancer cells, is often used alongside surgery in stage 1 mesothelioma treatment.

Chemotherapy may be used for stage 1 mesothelioma treatment to:

  • Prevent mesothelioma cells from spreading before, during, or after surgery
  • Kill off remaining cancer cells left behind after surgery

Many patients respond well to a combination of surgery and chemotherapy, potentially remaining disease-free for several months and surviving for years after treatment.

A 2015 study published in the journal Surgical Oncology reported that 19 peritoneal mesothelioma patients who underwent chemotherapy and surgery had a 100% 1-year survival rate and a 91% 3-year survival rate.

Radiation Therapy

Radiation, a therapy that uses radiation to control or kill cancer cells, is sometimes used to treat mesothelioma.

Radiation therapy may be used for stage 1 mesothelioma treatment to:

  • Kill remaining cells at the tumor site after surgery
  • Shrink tumors to make surgery easier
  • Prevent mesothelioma cells from being spread around the body during surgery

Before performing an EPP, mesothelioma specialists often use a practice called Surgery for Mesothelioma After Radiation Therapy (SMART). This approach seems to be effective at extending patient life.

A 2014 25-patient study published in the Journal of Thoracic Oncology found that, of the pleural mesothelioma epithelial cell type patients who underwent SMART, 84% had a 3-year survival rate.

Other Treatment Options

Stage 1 mesothelioma patients in good health usually turn to traditional treatment options to get the best results.

However, not all patients diagnosed early are good candidates for curative treatment options. These individuals may turn to clinical trials and the emerging therapies they offer in hopes of extending their lives.

Some emerging mesothelioma treatments include:

  • Anti-angiogenesis
  • Gene therapy
  • Immunotherapy
  • Photodynamic therapy

Patients seeking clinical trials should be aware of their cancer’s stage since many trials only test treatments on patients whose mesothelioma has progressed a certain amount.

Improving Your Stage 1 Mesothelioma Prognosis

The rare patient who receives a stage 1 mesothelioma diagnosis has an advantage when it comes to treatment options. However, even when caught in its earliest stages, mesothelioma is an aggressive disease with a poor overall prognosis.

Patients should give themselves every advantage when fighting mesothelioma to get the best prognosis possible.

Stage 1 mesothelioma patients may improve their prognosis by:

  • Eating well: Many peritoneal mesothelioma patients may struggle to meet their nutritional needs as their cancer progresses. However, getting the right nutrition boosts the immune system, giving patients undergoing treatment for any type of mesothelioma the best chance of survival and recovery.
  • Exercising: Exercise may decrease stress, improve blood flow, and help prevent bedsores and other secondary health problems.
  • Managing stress: High stress levels may affect overall health and patient recovery from treatments.
  • Not smoking: Smoking decreases overall patient health, making it harder — or impossible — to undergo and recover from invasive treatments. Smoking may also lead to another cancer diagnosis, decreasing life expectancy.
  • Seeking life-extending treatment: Many mesothelioma victims are diagnosed late in their cancer’s progression, leaving them unable to undergo radical treatments that may extend their lives by several months or even years. Patients diagnosed early should take advantage and seek curative treatments while they are able.

Doctors are studying current and new treatment options daily. Emerging cancer treatment options may soon give mesothelioma patients far better survival rates or even a cure.

Mesothelioma Support Team
Reviewed by:Dr. Assuntina Sacco

Board-Certified Oncologist

  • Fact-Checked
  • Editor

Assuntina Sacco, MD is an Associate Professor of Internal Medicine at the University of California, San Diego (UCSD) Moores Cancer Center, where she also serves as the Medical Director of Infusion Services. She is a board-certified medical oncologist trained to treat all solid tumor types, with the use of chemotherapy, immunotherapy, targeted therapy, and clinical trials.

Dr. Assuntina Sacco is an independently paid medical reviewer.

Stephanie KiddWritten by:

Editor-in-Chief

Stephanie Kidd grew up in a family of civil servants, blue-collar workers, and medical caregivers. Upon graduating Summa Cum Laude from Stetson University, she began her career specializing in worker safety regulations and communications. Now, a proud member of the American Medical Writers Association (AMWA) and Editor-in-Chief of the Mesothelioma Justice Network, Stephanie serves as a voice for mesothelioma victims and their families.

View 10 Sources
  1. Mott F. E. (2012). Mesothelioma: a review. The Ochsner journal, 12(1), 70–79. Retrieved January 21, 2020, from https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3307510/
  2. The American Cancer Society medical and editorial content team. (2018). Malignant Mesothelioma Stages. Retrieved January 21, 2020, from https://www.cancer.org/cancer/malignant-mesothelioma/detection-diagnosis-staging/staging.html
  3. Mayo Clinic Staff. (2019). Mesothelioma: Diagnosis & treatment. Retrieved January 21, 2020, from https://www.mayoclinic.org/diseases-conditions/mesothelioma/diagnosis-treatment/drc-20375028
  4. National Organization of Rare Disorders. (2017). Mesothelioma. Retrieved January 21, 2020, from https://rarediseases.org/rare-diseases/mesothelioma/
  5. Faig, J., Howard, S., Levine, E. A., Casselman, G., Hesdorffer, M., & Ohar, J. A. (2015). Changing pattern in malignant mesothelioma survival. Translational oncology, 8(1), 35–39. Retrieved January 21, 2020, from doi:10.1016/j.tranon.2014.12.002
  6. Amin, W., Linkov, F., Landsittel, D. P., Silverstein, J. C., Bashara, W., Gaudioso, C., … Becich, M. J. (2018). Factors influencing malignant mesothelioma survival: a retrospective review of the National Mesothelioma Virtual Bank cohort. F1000Research, 7, 1184. Retrieved January 21, 2020, from doi:10.12688/f1000research.15512.3
  7. Kim, J., Bhagwandin, S., & Labow, D. M. (2017). Malignant peritoneal mesothelioma: a review. Annals of translational medicine, 5(11), 236. Retrieved January 21, 2020, from doi:10.21037/atm.2017.03.96
  8. National Cancer Institute. (2015). Cancer Staging. Retrieved January 21, 2020, from https://www.cancer.gov/about-cancer/diagnosis-staging/staging
  9. Shavelle, R., Vavra-Musser, K., Lee, J., & Brooks, J. (2017). Life Expectancy in Pleural and Peritoneal Mesothelioma. Lung Cancer International. Retrieved January 21, 2020, from doi:10.1155/2017/2782590
  10. John Cho, B.C., Feld, R., Leighl, N., Opitz, I., Anraku, M., Tsao, M. … & Perrot, M. (2014). A Feasibility Study Evaluating Surgery for Mesothelioma After Radiation Therapy: The “SMART” Approach for Resectable Malignant Pleural Mesothelioma. Journal of Thoracic Oncology, 9(3), 397-402. Retrieved January 21, 2020, from https://doi.org/10.1097/JTO.0000000000000078
Back to Top